AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Blade Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 26, 2019

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 26, 2019--

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 31 st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 2:30 p.m. Eastern Time.

About Blade Therapeutics

Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade’s second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020.

Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit http://www.blademed.com/ for more

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005218/en/

CONTACT: Blade Therapeutics

Wendye Robbins, M.D., President and CEO

wrobbins@blademed.comBurns McClellan

Cameron Radinovic

Blade@burnsmc.com

212.213.0006

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Blade Therapeutics

Copyright Business Wire 2019.

PUB: 11/26/2019 08:00 AM/DISC: 11/26/2019 08:01 AM

http://www.businesswire.com/news/home/20191126005218/en